Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook

Ionis Pharmaceuticals stock has plummeted over 40% this year due to late-stage clinical trial failures and ongoing losses, yet Wall Street analysts maintain a bullish outlook with an average price target of $83.82. Despite setbacks with pelacarsen and eplontersen programs, the company's strong ASO technology platform, solid $2.1 billion cash position, and recent FDA approval of Zanvastro for Alexander disease provide potential for long-term investors willing to wait several years for profitability.

09/20/2026, 9:30 AM • The Motley Fool

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.

09/15/2026, 5:58 AM • GlobeNewswire

Hummingbird Bioscience Appoints Dr. James Garner as President

Hummingbird Bioscience announced the appointment of Dr. James Garner as President. Garner brings over two decades of experience in drug development and commercialization from roles at Biogen, Takeda, and Sanofi, with a track record of overseeing 30+ product approvals. He previously served as CEO of Percheron Therapeutics and Kazia Therapeutics.

09/15/2026, 5:00 AM • GlobeNewswire

Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

09/07/2026, 6:52 AM • GlobeNewswire

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

Canada's Drug Agency (CDA-AMC) has issued a final positive recommendation supporting public reimbursement of LEQEMBI (lecanemab) for patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease. The recommendation follows reconsideration and will proceed to negotiations through the pan-Canadian Pharmaceutical Alliance, with individual reimbursement decisions to follow from provincial and territorial drug plans.

08/31/2026, 7:30 PM • GlobeNewswire

Biogen Completes Acquisition of RayThera Inc.

Biogen Inc. announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company specializing in small-molecule immunology therapies. The acquisition adds multiple assets to Biogen's immunology portfolio, with the lead program entering Phase 1 development in July 2026. The company views this as part of its strategic growth in immunology and its open innovation model.

08/06/2026, 6:15 PM • GlobeNewswire

Why Supernus Pharmaceuticals Stock Topped the Market Today

Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.

08/03/2026, 6:05 PM • The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.

07/30/2026, 9:09 AM • The Motley Fool

Why Biogen Stock Topped the Market Today

Biogen stock gained nearly 2% after beating analyst estimates on both revenue ($2.7B, up 3% YoY) and adjusted EPS ($3.60 vs. $3.17 expected). The company's growth portfolio drove top-line improvement with 24% YoY revenue growth. Despite cutting full-year adjusted net income guidance to $12-$13 per share from $14.25-$15.25, investors remained positive as the company raised revenue guidance to mid-single-digit growth for 2025, signaling successful business pivot.

07/29/2026, 7:23 PM • The Motley Fool

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida

Grey Matters Health Inc. has received its first brain-dedicated PET scanning system (CareMiBrain) for its flagship NovaScan Neuroimaging Clinic in Davie, Florida, positioning itself as the first U.S. clinic to offer brain-only PET scans for early Alzheimer's detection. The clinic will capitalize on the emerging billion-dollar market created by FDA-approved monoclonal antibody treatments (Leqembi and Kisunla) that require beta-amyloid brain imaging for patient authorization and monitoring.

07/06/2026, 7:00 AM • GlobeNewswire

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth areas like Alzheimer's and rare diseases, with early signs of business stabilization and revenue growth.

07/04/2026, 4:02 AM • The Motley Fool

Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

A federal court has approved an $18.9 million settlement for investors who purchased Biogen Inc. common stock between June 8, 2021 and July 12, 2021. A settlement hearing is scheduled for September 29, 2026, to determine if the settlement is fair and reasonable. Class members must submit a Proof of Claim by September 24, 2026 to receive compensation.

06/29/2026, 8:00 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement of Phase 2 CELIA study results for diranersen (BIIB080), an Alzheimer's disease treatment. Although Biogen described the results as 'compelling,' the study missed its primary dose-response endpoint, causing the stock to fall $13.16 per share (6.43%) to $191.37 on May 14, 2026.

06/23/2026, 5:58 PM • GlobeNewswire